These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38339343)

  • 141. A new germline mutation in KIT associated with diffuse cutaneous mastocytosis in a Chinese family.
    Wang HJ; Lin ZM; Zhang J; Yin JH; Yang Y
    Clin Exp Dermatol; 2014 Mar; 39(2):146-9. PubMed ID: 24289326
    [TBL] [Abstract][Full Text] [Related]  

  • 142. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 143. Mast cell leukemia.
    Georgin-Lavialle S; Lhermitte L; Dubreuil P; Chandesris MO; Hermine O; Damaj G
    Blood; 2013 Feb; 121(8):1285-95. PubMed ID: 23243287
    [TBL] [Abstract][Full Text] [Related]  

  • 144. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.
    Kristensen T; Vestergaard H; Møller MB
    J Mol Diagn; 2011 Mar; 13(2):180-8. PubMed ID: 21354053
    [TBL] [Abstract][Full Text] [Related]  

  • 145. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.
    Pardanani A; Lim KH; Lasho TL; Finke C; McClure RF; Li CY; Tefferi A
    Blood; 2009 Oct; 114(18):3769-72. PubMed ID: 19713463
    [TBL] [Abstract][Full Text] [Related]  

  • 146. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.
    Lim KH; Tefferi A; Lasho TL; Finke C; Patnaik M; Butterfield JH; McClure RF; Li CY; Pardanani A
    Blood; 2009 Jun; 113(23):5727-36. PubMed ID: 19363219
    [TBL] [Abstract][Full Text] [Related]  

  • 147. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.
    Lanternier F; Cohen-Akenine A; Palmerini F; Feger F; Yang Y; Zermati Y; Barète S; Sans B; Baude C; Ghez D; Suarez F; Delarue R; Casassus P; Bodemer C; Catteau A; Soppelsa F; Hanssens K; Arock M; Sobol H; Fraitag S; Canioni D; Moussy A; Launay JM; Dubreuil P; Hermine O; Lortholary O;
    PLoS One; 2008 Apr; 3(4):e1906. PubMed ID: 18404201
    [TBL] [Abstract][Full Text] [Related]  

  • 148. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
    Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
    Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
    [TBL] [Abstract][Full Text] [Related]  

  • 149. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.
    Garcia-Montero AC; Jara-Acevedo M; Teodosio C; Sanchez ML; Nunez R; Prados A; Aldanondo I; Sanchez L; Dominguez M; Botana LM; Sanchez-Jimenez F; Sotlar K; Almeida J; Escribano L; Orfao A
    Blood; 2006 Oct; 108(7):2366-72. PubMed ID: 16741248
    [TBL] [Abstract][Full Text] [Related]  

  • 150. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
    Zhang LY; Smith ML; Schultheis B; Fitzgibbon J; Lister TA; Melo JV; Cross NC; Cavenagh JD
    Leuk Res; 2006 Apr; 30(4):373-8. PubMed ID: 16183119
    [TBL] [Abstract][Full Text] [Related]  

  • 151. Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in
    Naumann N; Rudelius M; Lübke J; Christen D; Bresser J; Sotlar K; Metzgeroth G; Fabarius A; Hofmann WK; Panse J; Horny HP; Cross NCP; Reiter A; Schwaab J
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339343
    [TBL] [Abstract][Full Text] [Related]  

  • 152. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 153. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.
    McLornan DP; Czerw T; Damaj G; Ethell M; Gurnari C; Hernández-Boluda JC; Polverelli N; Schwaab J; Sockel K; Raffaella G; Onida F; Sánchez-Ortega I; Battipaglia G; Elena C; Gotlib J; Reiter A; Rossignol J; Ustun C; Valent P; Yakoub-Agha I; Radia DH
    Leukemia; 2024 Apr; 38(4):699-711. PubMed ID: 38472477
    [TBL] [Abstract][Full Text] [Related]  

  • 154. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
    Valent P; Akin C; Arock M; Gleixner KV; Greinix H; Hermine O; Horny HP; Ivanov D; Orfao A; Rabitsch W; Reiter A; Schulenburg A; Sotlar K; Sperr WR; Ustun C
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894806
    [TBL] [Abstract][Full Text] [Related]  

  • 155. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
    Reiter A; George TI; Gotlib J
    Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
    [TBL] [Abstract][Full Text] [Related]  

  • 156. Precision Medicine in Systemic Mastocytosis.
    Nicolosi M; Patriarca A; Andorno A; Mahmoud AM; Gennari A; Boldorini R; Gaidano G; Crisà E
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833353
    [TBL] [Abstract][Full Text] [Related]  

  • 157. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 158. Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.
    Tashi T; Deininger MW
    Immunol Allergy Clin North Am; 2023 Nov; 43(4):723-741. PubMed ID: 37758409
    [TBL] [Abstract][Full Text] [Related]  

  • 159. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
    Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
    [TBL] [Abstract][Full Text] [Related]  

  • 160. Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis.
    Veitch S; Radia DH
    Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.